Research progress of phosphatidylinositol 3-kinase/AKt signaling pathway and mechanisms of resistance to sorafenib in hepatocellular carcinoma
10.3760/cma.j.issn.1673-4203.2015.10.020
- VernacularTitle:PI3K/AKt信号通路与肝癌对索拉菲尼耐药机制的研究进展
- Author:
Jiejie DONG
;
Bo ZHAI
;
Jun XU
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Drug resistance,neoplasms;
Treatment outcome
- From:
International Journal of Surgery
2015;42(10):709-713
- CountryChina
- Language:Chinese
-
Abstract:
Sorafenib is a molecular targeted drug for the treatment of advanced primary liver cancer.However,along with the occurrence of drug resistance,the therapeutic effect was effected.At present,there is clear evidence that the emergence of drug resistance of live cancer is closely related to the epithelial-mesenchymal transition,liver cancer stem cells and the heterogeneity of liver cancer,and the PI3K/AKt signaling pathway as the vital common signaling channel was involved in the above mentioned process.From this we can conclude that complementary inhibtion of PI3K/AKt signaling pathway at the same time is the method that can strengthen the effect of sorafenib on the treatment of liver cancer so far.
